Revolution Medicines Inc (NASDAQ: RVMD) released preliminary data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the
The Food and Drug Administration (FDA) approved Pfizer Inc's (NYSE: PFE) Velsipity (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active
Harmony Biosciences Holdings Inc (NASDAQ: HRMY) announced topline results from the INTUNE Phase 3 study of pitolisant in patients with idiopathic hypersomnia (IH).
Cassava Sciences Inc (NASDAQ: SAVA), the Alzheimer-focused firm, is facing further controversy as a recent investigation by the City University of New York (CUNY) has implicated neuroscientist Hoau-Yan Wang, a long-time collaborator of Cassava, in scientific misconduct related to 20 research papers.&nb